In Brief: Bayer/Andrx
This article was originally published in The Tan Sheet
Executive Summary
Bayer/Andrx: Enter agreement to develop a new OTC product using Ft. Lauderdale, Fla.-based Andrx' controlled-release drug delivery technologies and a Bayer affiliate's OTC expertise, Andrx announces Sept. 22. Details were not disclosed. Given the move to switch Rx products to OTCs, Andrx considers the arrangement with Bayer the "beginning of an ongoing relationship"...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning